Literature DB >> 5843261

Evidence for parathyroid hormone in nonparathyroid tumors associated with hypercalcemia.

P L Munson, A H Tashjian, L Levine.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1965        PMID: 5843261

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


× No keyword cloud information.
  8 in total

1.  Association of ectopically produced hyperparathyroidism with hepatoma.

Authors:  R P Dunn; J S Nystrom
Journal:  Calif Med       Date:  1973-01

Review 2.  Peptide-secreting tumours with special reference to the pancreas.

Authors:  W Sircus
Journal:  Gut       Date:  1969-07       Impact factor: 23.059

Review 3.  The clinical physiology of calcium homeostasis, parathyroid hormone, and calcitonin. II.

Authors:  C R Kleeman; S G Massry; J W Coburn
Journal:  Calif Med       Date:  1971-04

4.  Ectopic secretion of parathyroid hormone by a renal adenocarcinoma in a patient with hypercalcaemia.

Authors:  R M Buckle; M McMillan; C Mallinson
Journal:  Br Med J       Date:  1970-12-19

5.  Immunoreactive forms of circulating parathyroid hormone in primary and ectopic hyperparathyroidism.

Authors:  R C Benson; B L Riggs; B M Pickard; C D Arnaud
Journal:  J Clin Invest       Date:  1974-07       Impact factor: 14.808

6.  Hypercalcaemia in malignant lymphoma.

Authors:  M Greaves; B W Hancock
Journal:  Postgrad Med J       Date:  1980-01       Impact factor: 2.401

7.  Immunologic differentiation of primary hyperparathyroidism from hyperparathyroidism due to nonparathyroid cancer.

Authors:  B L Riggs; C D Arnaud; J C Reynolds; L H Smith
Journal:  J Clin Invest       Date:  1971-10       Impact factor: 14.808

8.  Evidence that the bone resorption-stimulating factor produced by mouse fibrosarcoma cells is prostaglandin E 2 . A new model for the hypercalcemia of cancer.

Authors:  A H Tashjian; E F Voelkel; L Levine; P Goldhaber
Journal:  J Exp Med       Date:  1972-12-01       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.